Breaking News, Collaborations & Alliances

Pierre Fabre and Lonza Enter Manufacturing Agreement

Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate, from its fill-finish facility in Stein, Switzerland.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre, have entered into a manufacturing agreement. This collaboration is aimed at manufacturing W0180, an innovative monoclonal antibody discovered by Pierre Fabre targeting the VISTA checkpoint, currently being investigated as a single agent and in combination with pembrolizumab in a Phase I clinical trial (NCT04564417) in various solid tumors. Lon...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters